Cargando…

Should We Monitor Glucose and Biomarkers in Diabetics over Heart Surgery?

Hyperglycemia is associated with adverse outcomes after coronary artery bypass grafting (CABG). While there is a consensus that blood glucose control may benefit patients undergoing CABG, the role of biomarkers, optimal method, and duration of such monitoring are still unclear. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golukhova, Elena Z., Lifanova, Ljubov S., Pugovkina, Yaroslava V., Grigoryan, Marina V., Bulaeva, Naida I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348301/ https://www.ncbi.nlm.nih.gov/pubmed/34362176 http://dx.doi.org/10.3390/jcm10153399

Ejemplares similares

Prognostic Value of Characterizing Myocardial Tissue by Cardiac MRI with T1 Mapping in HFpEF Patients: A Systematic Review and Meta-Analysis
por: Golukhova, Elena, et al.
Publicado: (2022)

ACE phenotyping in human heart
por: Tikhomirova, Victoria E., et al.
Publicado: (2017)

Conformational fingerprint of blood and tissue ACEs: Personalized approach
por: Danilov, Sergei M., et al.
Publicado: (2018)

Human Angiotensin I-Converting Enzyme Produced by Different Cells: Classification of the SERS Spectra with Linear Discriminant Analysis
por: Boginskaya, Irina, et al.
Publicado: (2022)

Monogenec Arrhythmic Syndromes: From Molecular and Genetic Aspects to Bedside
por: E.Z., Golukhova, et al.
Publicado: (2016)

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Elimination of avoidable blindness due to cataract: Where do we prioritize and how should we monitor this decade?
por: Murthy, Gudlavalleti V S, et al.
Publicado: (2012)

Electroencephalography as a Tool for Assessment of Brain Ischemic Alterations after Open Heart Operations
por: Golukhova, Elena Z., et al.
Publicado: (2011)

Physical activity and heart rate monitoring in Fontan patients – Should we recommend activities in higher intensities?
por: Härtel, Julian Alexander, et al.
Publicado: (2020)

Should We Be Ablating the Kidneys or the Heart to Prevent Arrhythmias?
por: Wilson, Lance D., et al.
Publicado: (2017)

Calcaneal Fractures – Should We or Should We not Operate?
por: Rammelt, Stefan, et al.
Publicado: (2018)

Size of Left Cardiac Chambers Correlates with Cerebral Microembolic Load in Open Heart Operations
por: Golukhova, Elena Z., et al.
Publicado: (2010)

Should we resect colorectal cancer in patients over the age of 85?
por: Flynn, David E, et al.
Publicado: (2021)

When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention
por: Iguchi, Moritake, et al.
Publicado: (2023)

Should We Use an Orphan Graft?
por: Baskıran, A., et al.
Publicado: (2017)

We Can, but Should We?
por: Kelly, Robert Brett
Publicado: (2016)

Atrial fibrillation in heart failure: what should we do?
por: Kotecha, Dipak, et al.
Publicado: (2015)

‘Acute Heart Failure’: Should We Abandon the Term Altogether?
por: Straw, Sam, et al.
Publicado: (2022)

Should We Be Screening for Ischaemic Heart Disease Earlier in Childhood?
por: Bassareo, Pier Paolo, et al.
Publicado: (2022)

How Should We Think About the Role of the Brain in Glucose Homeostasis and Diabetes?
por: Deem, Jennifer D., et al.
Publicado: (2017)

Should We Monitor ScVO(2) in Critically Ill Patients?
por: Nebout, Sophie, et al.
Publicado: (2012)

Which lipid measurement should we monitor? An analysis of the LIPID study
por: Glasziou, Paul P, et al.
Publicado: (2014)

Monitoring the prevalence of chronic conditions: which data should we use?
por: Orueta, Juan F, et al.
Publicado: (2012)

Why should we monitor for hematologic adverse drug reactions to oxcarbazepine?
por: Jang, Gwang Cheon
Publicado: (2019)

When and how should we cluster and cross over: methodological and ethical issues
por: Goldstein, Cory E., et al.
Publicado: (2018)

Self-management in heart failure: where have we been and where should we go?
por: Gardetto, Nancy Jean
Publicado: (2011)

Where should we start to improve pediatric heart transplantation outcomes?
por: Song, Jinyoung
Publicado: (2020)

Bioimpedance Vector Analysis for Heart Failure: Should We Put It on the Agenda?
por: Liang, Bo, et al.
Publicado: (2021)

Which Phenotypes Should We Include in the Hypoplastic Left Heart Syndrome?
por: Anderson, Robert H., et al.
Publicado: (2023)

Microbiome: Should we diversify from diversity?
por: Johnson, Katerina V.-A., et al.
Publicado: (2016)

Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
por: Kalogeropoulou, Maria-Sofia, et al.
Publicado: (2023)

Should we be Royal?
por: Kealy-Bateman, Warren, et al.
Publicado: (2021)

Cardiac output monitoring by echocardiography: should we pass on Swan-Ganz catheters?
por: Perrino, A. C.
Publicado: (1993)

AB021. What and how should we monitor to diagnose and treat hypogonadism?
por: Park, Jong Kwan
Publicado: (2016)

How should we monitor marketing foods to children for their better eating habits?
por: Gregorio, M J
Publicado: (2023)

Live operative workshops: Should we do away with them?
por: Chandrasekharam, V. V. S., et al.
Publicado: (2013)

Intracranial Pressure Monitoring for Acute Brain Injured Patients: When, How, What Should We Monitor
por: Shim, Youngbo, et al.
Publicado: (2023)

AB132. Nocturnal penile tumescence monitoring: what have we done and what should we do?
por: Gao, Liang, et al.
Publicado: (2015)

Can we, should we, eradicate the meningococcus?
por: Maiden, Martin C.J., et al.
Publicado: (2012)

REBOA for trauma: Could we? Should we?
por: DeLaney, Matthew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p1db0uklf0btpfkcg3rlqm9b8p